<DOC>
	<DOCNO>NCT01859325</DOCNO>
	<brief_summary>Background : - In people human immunodeficiency virus ( HIV ) , immune system control cure infection . Antiretroviral therapy drug keep amount HIV virus low long time . However , treatment remove virus body . In vast majority patient antiretroviral therapy also protect body virus treatment stop . Researchers want see therapeutic vaccination help people HIV . Therapeutic vaccination mean give vaccine treat infection someone already ( HIV , case ) . It may help body 's immune system attack infection . This study look different measure HIV infection receive either therapeutic vaccination placebo . Objectives : - To see whether therapeutic vaccination safe affect body respond HIV infection . Eligibility : - Individuals 18 65 year age HIV take antiretroviral therapy drug . Design : - Participants screen physical exam medical history . Blood urine sample collect . - During screen visit throughout study week 56 , participant continue take HIV medication . - Participants divide two group . One group study vaccine . The placebo . - The first study vaccine placebo give week 4 , 12 , 36 . The second study vaccine placebo give week 24 48 . Blood sample test give visit . - After study visit week 56 , participant stop HIV medication week 72 . From week 58 72 , come every 2 week study visit ; visit take 1 hour complete . These visit look body response vaccine HIV viral load . After week 72 , participant re-start HIV medication . - There follow-up study visit week 76 96 , blood test study .</brief_summary>
	<brief_title>Therapeutic Vaccine HIV</brief_title>
	<detailed_description>The advent combination antiretroviral therapy ( cART ) dramatically improve clinical outcome human immunodeficiency virus ( HIV ) -infected individual sustain reduction viral replication . However , become clear cART alone eradicate HIV infected individual , likely part due persistence viral reservoir peripheral blood various tissue compartment . Consequently , major thrust HIV research past several year develop therapeutic strategy eliminate persistent viral reservoir boost host immunity control viral replication upon discontinuation cART . Therapeutic HIV vaccination one approach could potentially achieve goal vaccine-induced improvement HIV-specific immune response and/or direct reactivation HIV-specific CD4+ memory T cell harbor latent HIV . An effective therapeutic vaccine could augment immunologic control HIV infection potentially obviate need chronic cART . The current study exploratory randomize , 2-arm ( 1:1 ) , double-blind , placebo-controlled trial evaluate safety efficacy HIV-1 multiantigen plasmid DNA ( HIV-MAG pDNA ) vaccine prime combination interleukin-12 plasmid DNA ( IL-12 pDNA ) adjuvant deliver vivo electroporation follow recombinant vesicular stomatitis virus vector contain HIV-1 gag gene ( rVSV HIV gag ) booster vaccine subject cART start therapy acute early HIV infection . Subjects randomize receive placebo HIV-MAG pDNA ( 3000 g ) vaccine prime IL-12 pDNA adjuvant ( 1000 g ) week 0 , 4 , 12 , 36 , rVSV HIV gag booster vaccine ( 1x107 plaque-forming unit ) week 24 48 . The HIV-MAG pDNA vaccine prime IL-12 pDNA adjuvant administer 2 IM injection , 1 deltoid , electroporation use Ichor TDS device , rVSV HIV gag booster vaccine administer 2 conventional IM injection , 1 deltoid . After week 56 visit , subject undergo analytical treatment interruption determine vaccination strategy result improve immune control viral replication , evidence blunt absent rebound HIV plasma viremia . All subject follow week 96 safety efficacy parameter . The study population include HIV-infected adult begin cART acute early infection . Subjects must receive effective cART regimen , CD4 cell count &gt; 450 cells/mm3 screening , must document viral suppression limit detection great than1 year . The rationale test study vaccine regimen subject population individual may relatively preserve immune function , could augment therapeutic vaccination .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Age , 1865 year . 2 . Institution cART within 12 week diagnose acute early HIV1 infection . Acute HIV1 infection define : 1 . Detectable plasma HIV1 RNA level great 2000 copies/mL negative result HIV1 EIA , 2 . Positive result HIV1 EIA negative indeterminate result HIV1 western blot subsequently evolve confirm positive result , 3 . Negative result HIV1 EIA within past 4 month HIV1 RNA level great 400,000 copies/mL , set potential exposure HIV1 . Early HIV1 Infection define : 1 . Negative result HIV1 EIA within 6 month prior positive result HIV1 EIA HIV1 western blot . 2 . Negative result rapid HIV1 test within 1 month prior positive result HIV1 EIA HIV1 western blot . 3 . Presence low level HIV antibody determine positive EIA positive Western blot nonreactive detuned EIA accord serologic testing algorithm recent infection . 3 . CD4+ cell count great 450 cells/mm3 screening . 4 . Documentation continuous cART treatment suppression plasma viral level limit detection great 1 year . Subjects single blip ( i.e. , detectable viral level cART ) prior randomization may include provide satisfy follow criterion : 1 . The blip le 400 copies/mL , 2 . Succeeding viral level return level limit detection subsequent testing . 5 . Willingness undergo ATI . 6 . Laboratory value within predefined limit screen : Absolute neutrophil count great 1,000/mm3 . Hemoglobin level great 10.0 g/dL men great 9.0 g/dL woman . Platelet count great 100,000/mm3 . Prothrombin time ( PT ) partial thromboplastin time ( PTT ) less 1.5 upper limit normal ( ULN ) . Estimated measured creatinine clearance rate great 60 mL/min determine NIH Clinical Center laboratory . AST ALT level less 2.5 x ULN . 7 . Willingness sample store future research . 8 . Women childbearing potential must negative pregnancy test result . They must agree use adequate form contraception : Hormonal contraception . Male female condom without spermicidal Diaphragm cervical cap spermicidal . Intrauterine device . EXCLUSION CRITERIA : 1 . Allergy amidetype local anesthetic ( bupivacaine ( Marcaine ) , lidocaine ( Xylocaine ) , Mepivacaine ( Polocaine/Carbocaine ) , etidocaine ( Duranest ) , prilocaine ( Citanest , EMLA cream ) . 2 . Chronic hepatitis B , evidence positive test hepatitis B surface antigen ( HBsAg ) , chronic hepatitis C virus ( HCV ) infection , evidence positive test HCV RNA . Subjects positive test HCV antibody negative test HCV RNA eligible . 3 . Changes cART regimen due virologic breakthrough . 4 . HIV immunotherapy vaccine ( ) receive within 1 year prior screen . 5 . Any licensed experimental nonHIV vaccination ( e.g. , hepatitis B , influenza , pneumococcal polysaccharide ) receive within 4 week prior study entry . 6 . Interruption cART great 3 month since initiation . 8 . Any active malignancy may require systemic chemotherapy radiation therapy . 7 . Pregnancy plan pregnancy study period breastfeed . 8 . Any active malignancy may require systemic chemotherapy radiationtherapy . 9 . Immunosuppressive medication receive within 6 month first study vaccination ( Not exclude : ( 1 ) corticosteroid nasal spray allergic rhinitis ; ( 2 ) topical corticosteroid mild , uncomplicated dermatitis ; ( 3 ) oral/parenteral corticosteroid administer nonchronic condition expect recur ( length therapy less equal to10 day , completion great equal 30 day prior enrollment ) . 10 . Evidence hepatic decompensation subject cirrhosis : history ascites , hepatic encephalopathy , bleed esophageal varix , screen laboratory result follow : 1. International normalized ratio great equal to1.5 x ULN . 2 . Serum albumin less 3.2 g/dL . 3 . Serum total bilirubin great 1.8 x ULN , unless history Gilbert 's disease deem related treatment atazanavir . 11 . History clinical evidence : 1 . Significant unstable cardiac disease ( e.g. , angina , congestive heart failure , recent myocardial infarction , significant arrhythmia ) . 2 . Severe illness , malignancy , immunodeficiency HIV , condition , opinion investigator , would make subject unsuitable study . 3 . AIDSdefining condition . 12 . Known allergy sensitivity component investigational therapy . 13 . History significant cardiac arrhythmia ( e.g. , supraventricular tachycardia , ventricular tachycardia , atrial fibrillation/flutter ) . 14 . Active drug alcohol use dependence pattern behaivor , opinion investigator , would interfere adherence study requirement . 15 . Any active systemic inflammatory autoimmune disease condition . 16 . Presence implant electronic medical device ( e.g. , pacemaker , implantable cardiac defibrillator ) surgical/traumatic metal implant upper limb and/or upper torso . 17 . Neurological neuropsychiatric disorder may interfere assessment safety ( e.g. , frequent recur headache , example , pattern great 1 headache/month affect activity daily living/work , frequent severe/complicated migraine , cluster headache ) ; history encephalitis , narcolepsy , stroke sequela , moderate/severe major depressive disorder , moderate/severe bipolar disorder , seizure disorder . 18 . Deltoid skinfold measurement ( caliper ) great 40 mm . 19 . Body mass index great 40 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 10, 2017</verification_date>
	<keyword>HIV-MAG pDNA Prime</keyword>
	<keyword>HIV Therapy</keyword>
	<keyword>Therapeutic Vaccine</keyword>
</DOC>